Liquidia infringes two United Therapeutics patent claims in Yutrepia Hatch-Waxman case, judge rules

Bitget2026/09/30 17:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Delaware federal court found Liquidia’s YUTREPIA infringed two asserted claims of United Therapeutics’ U.S. Patent No. 11,826,327.
Court upheld claims 1 and 14 as valid and infringed; other asserted claims were ruled invalid.
Parties must submit a proposed judgment within one week, including remedies for the infringement finding.
Potential remedies include removing the PH-ILD indication from YUTREPIA’s label or broader limits on market availability.
Liquidia plans to appeal, citing disagreement with the ruling on the two upheld claims.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301320PRIMZONEFULLFEED9837151) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Liquidia infringes two United Therapeutics patent claims in Yutrepia Hatch-Waxman case, judge rules

You may also like

Crypto prices